John Babich, PhD profile page

John W. Babich, a native of New York City, holds a BS in pharmaceutical sciences from St. John’s University and a PhD in radiopharmaceutical chemistry from The Institute of Cancer Research in London. He began his career at Brookhaven National Laboratory and later NASA, focusing on cardiovascular imaging. Babich co-founded Molecular Insight Pharmaceuticals in 1998, where he developed several radiopharmaceuticals, including a PSMA inhibitor for prostate cancer now in Phase 3 trials. In 2017, he founded Noria Therapeutics, which was sold to Bayer in 2021, leading to the creation of Ratio Therapeutics.